Build Your Comparison

Side-by-side financial analysis
MAIA logo
MAIA
TPVG logo
TPVG
HRZN logo
HRZN
TELO logo
TELO
JPM logo
JPM
Try popular comparisons:

Stock Comparison

MAIA vs TPVG vs HRZN vs TELO vs JPM

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
MAIA
MAIA Biotechnology, Inc.

Biotechnology

HealthcareAMEX • US
Market Cap$50M
5Y Perf.-0.8%
TPVG
TriplePoint Venture Growth BDC Corp.

Asset Management

Financial ServicesNYSE • US
Market Cap$226M
5Y Perf.-48.3%
HRZN
Horizon Technology Finance Corporation

Asset Management

Financial ServicesNASDAQ • US
Market Cap$192M
5Y Perf.-63.5%
TELO
Telomir Pharmaceuticals, Inc. Common Stock

Biotechnology

HealthcareNASDAQ • US
Market Cap$43M
5Y Perf.-86.1%
JPM
JPMorgan Chase & Co.

Banks - Diversified

Financial ServicesNYSE • US
Market Cap$896.00B
5Y Perf.+72.4%

MAIA vs TPVG vs HRZN vs TELO vs JPM — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
MAIA logoMAIA
TPVG logoTPVG
HRZN logoHRZN
TELO logoTELO
JPM logoJPM
IndustryBiotechnologyAsset ManagementAsset ManagementBiotechnologyBanks - Diversified
Market Cap$50M$226M$192M$43M$896.00B
Revenue (TTM)$0.00$61M$75M$0.00$280.33B
Net Income (TTM)$-24M$-12M$28M$-9M$57.05B
Gross Margin72.9%35.7%60.0%
Operating Margin-35.9%26.0%25.9%
Forward P/E6.0x6.5x14.4x
Total Debt$0.00$469M$473M$0.00$942.38B
Cash & Equiv.$8.66B$20M$106M$7M$343.34B

MAIA vs TPVG vs HRZN vs TELO vs JPMLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

MAIA
TPVG
HRZN
TELO
JPM
StockFeb 24Jun 26Return
MAIA Biotechnology,… (MAIA)10099.2-0.8%
TriplePoint Venture… (TPVG)10051.7-48.3%
Horizon Technology … (HRZN)10036.5-63.5%
Telomir Pharmaceuti… (TELO)10013.9-86.1%
JPMorgan Chase & Co. (JPM)100172.4+72.4%

Price return only. Dividends and distributions are not included.

Quick Verdict: MAIA vs TPVG vs HRZN vs TELO vs JPM

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: HRZN leads in 4 of 7 categories (5-stock set), making it the strongest pick for valuation and capital efficiency and profitability and margin quality. TriplePoint Venture Growth BDC Corp. is the stronger pick specifically for capital preservation and lower volatility. TELO and JPM also each lead in at least one category. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
🥇HRZN emerged as the overall leader. Track its performance:
MAIA
MAIA Biotechnology, Inc.
The Healthcare Pick

Among these 5 stocks, MAIA doesn't own a clear edge in any measured category.

Best for: healthcare exposure
TPVG
TriplePoint Venture Growth BDC Corp.
The Banking Pick

TPVG is the #2 pick in this set and the best alternative if growth exposure and sleep-well-at-night is your priority.

  • Rev growth 36.6%, EPS growth 48.8%
  • Lower volatility, beta 0.65
  • NIM 7.4% vs JPM's 2.2%
  • Beta 0.65 vs MAIA's 1.84
Best for: growth exposure and sleep-well-at-night
HRZN
Horizon Technology Finance Corporation
The Banking Pick

HRZN carries the broadest edge in this set and is the clearest fit for income & stability and valuation efficiency.

  • Dividend streak 1 yrs, beta 0.85, yield 28.8%
  • PEG 0.27 vs TPVG's 5.88
  • Beta 0.85, yield 28.8%, current ratio 1.24x
  • Lower P/E (6.5x vs 14.4x), PEG 0.27 vs 0.81
Best for: income & stability and valuation efficiency
TELO
Telomir Pharmaceuticals, Inc. Common Stock
The Growth Leader

TELO ranks third and is worth considering specifically for growth.

  • 241.7% revenue growth vs MAIA's -3.6%
Best for: growth
JPM
JPMorgan Chase & Co.
The Banking Pick

JPM is the clearest fit if your priority is long-term compounding.

  • 465.8% 10Y total return vs TPVG's 85.3%
  • +21.8% vs TELO's -37.0%
Best for: long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthTELO logoTELO241.7% revenue growth vs MAIA's -3.6%
ValueHRZN logoHRZNLower P/E (6.5x vs 14.4x), PEG 0.27 vs 0.81
Quality / MarginsHRZN logoHRZN37.4% margin vs TPVG's -19.5%
Stability / SafetyTPVG logoTPVGBeta 0.65 vs MAIA's 1.84
DividendsHRZN logoHRZN28.8% yield, 1-year raise streak, vs JPM's 1.9%, (2 stocks pay no dividend)
Momentum (1Y)JPM logoJPM+21.8% vs TELO's -37.0%
Efficiency (ROA)HRZN logoHRZN3.6% ROA vs TELO's -172.7%

MAIA vs TPVG vs HRZN vs TELO vs JPM — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

MAIAMAIA Biotechnology, Inc.

Segment breakdown not available.

TPVGTriplePoint Venture Growth BDC Corp.

Segment breakdown not available.

HRZNHorizon Technology Finance Corporation

Segment breakdown not available.

TELOTelomir Pharmaceuticals, Inc. Common Stock

Segment breakdown not available.

JPMJPMorgan Chase & Co.
FY 2025
Commercial And Investment Bank
43.0%$78.5B
Consumer & Community Banking
41.7%$76.0B
Asset and Wealth Management Segment
13.2%$24.1B
Segment Reporting, Reconciling Item, Corporate Nonsegment
3.9%$7.0B
Segment Reconciling Items
-1.7%$-3,134,000,000

MAIA vs TPVG vs HRZN vs TELO vs JPM — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLHRZNLAGGINGTELO

Income & Cash Flow (Last 12 Months)

HRZN leads this category, winning 3 of 5 comparable metrics.

JPM and TELO operate at a comparable scale, with $280.3B and $0 in trailing revenue. HRZN is the more profitable business, keeping 37.4% of every revenue dollar as net income compared to TPVG's -19.5%.

MetricMAIA logoMAIAMAIA Biotechnolog…TPVG logoTPVGTriplePoint Ventu…HRZN logoHRZNHorizon Technolog…TELO logoTELOTelomir Pharmaceu…JPM logoJPMJPMorgan Chase & …
RevenueTrailing 12 months$0$61M$75M$0$280.3B
EBITDAEarnings before interest/tax-$16M-$22M$19M-$9M$81.4B
Net IncomeAfter-tax profit-$24M-$12M$28M-$9M$57.0B
Free Cash FlowCash after capex-$20M-$59M$67M-$5M$100.9B
Gross MarginGross profit ÷ Revenue+72.9%+35.7%+60.0%
Operating MarginEBIT ÷ Revenue-35.9%+26.0%+25.9%
Net MarginNet income ÷ Revenue-19.5%+37.4%+20.4%
FCF MarginFCF ÷ Revenue-97.1%+89.6%+36.0%
Rev. Growth (YoY)Latest quarter vs prior year
EPS Growth (YoY)Latest quarter vs prior year+12.5%-2.3%-29.6%+59.0%+16.0%
HRZN leads this category, winning 3 of 5 comparable metrics.

Valuation Metrics

Evenly matched — TPVG and HRZN each lead in 3 of 7 comparable metrics.

At 4.2x trailing earnings, HRZN trades at a 74% valuation discount to JPM's 16.0x P/E. Adjusting for growth (PEG ratio), HRZN offers better value at 0.17x vs TPVG's 4.50x — a lower PEG means you pay less per unit of expected earnings growth.

MetricMAIA logoMAIAMAIA Biotechnolog…TPVG logoTPVGTriplePoint Ventu…HRZN logoHRZNHorizon Technolog…TELO logoTELOTelomir Pharmaceu…JPM logoJPMJPMorgan Chase & …
Market CapShares × price$50M$226M$192M$43M$896.0B
Enterprise ValueMkt cap + debt − cash-$8.6B$675M$560M$36M$1.50T
Trailing P/EPrice ÷ TTM EPS-1.86x4.57x4.15x-3.82x16.00x
Forward P/EPrice ÷ next-FY EPS est.5.96x6.50x14.40x
PEG RatioP/E ÷ EPS growth rate4.50x0.17x0.90x
EV / EBITDAEnterprise value multiple8.91x18.36x
Price / SalesMarket cap ÷ Revenue2.33x4.81x3.20x
Price / BookPrice ÷ Book value/share17.57x0.63x0.58x6.74x2.47x
Price / FCFMarket cap ÷ FCF3.40x8.88x
Evenly matched — TPVG and HRZN each lead in 3 of 7 comparable metrics.

Profitability & Efficiency

Evenly matched — TPVG and JPM each lead in 3 of 9 comparable metrics.

JPM delivers a 15.9% return on equity — every $100 of shareholder capital generates $16 in annual profit, vs $-2 for TELO. TPVG carries lower financial leverage with a 1.33x debt-to-equity ratio, signaling a more conservative balance sheet compared to JPM's 2.60x. On the Piotroski fundamental quality scale (0–9), HRZN scores 5/9 vs MAIA's 2/9, reflecting solid financial health.

MetricMAIA logoMAIAMAIA Biotechnolog…TPVG logoTPVGTriplePoint Ventu…HRZN logoHRZNHorizon Technolog…TELO logoTELOTelomir Pharmaceu…JPM logoJPMJPMorgan Chase & …
ROE (TTM)Return on equity-4.0%-3.4%+9.0%-2.0%+15.9%
ROA (TTM)Return on assets-1.0%-1.5%+3.6%-172.7%+1.3%
ROICReturn on invested capital+7.2%-0.2%+4.5%
ROCEReturn on capital employed-4.8%+9.4%-0.2%-3.2%+8.9%
Piotroski ScoreFundamental quality 0–924535
Debt / EquityFinancial leverage1.33x1.49x2.60x
Net DebtTotal debt minus cash-$8.7B$449M$368M-$7M$599.0B
Cash & Equiv.Liquid assets$8.7B$20M$106M$7M$343.3B
Total DebtShort + long-term debt$0$469M$473M$0$942.4B
Interest CoverageEBIT ÷ Interest expense-1.02x0.60x-1740.57x0.74x
Evenly matched — TPVG and JPM each lead in 3 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

JPM leads this category, winning 6 of 6 comparable metrics.

A $10,000 investment in JPM five years ago would be worth $21,820 today (with dividends reinvested), compared to $1,800 for TELO. Over the past 12 months, JPM leads with a +21.8% total return vs TELO's -37.0%. The 3-year compound annual growth rate (CAGR) favors JPM at 33.6% vs TELO's -43.5% — a key indicator of consistent wealth creation.

MetricMAIA logoMAIAMAIA Biotechnolog…TPVG logoTPVGTriplePoint Ventu…HRZN logoHRZNHorizon Technolog…TELO logoTELOTelomir Pharmaceu…JPM logoJPMJPMorgan Chase & …
YTD ReturnYear-to-date-18.8%-12.7%-28.1%-6.0%-0.5%
1-Year ReturnPast 12 months-25.7%-10.7%-26.7%-37.0%+21.8%
3-Year ReturnCumulative with dividends-47.4%-22.4%-31.5%-82.0%+138.2%
5-Year ReturnCumulative with dividends-70.9%-23.3%-39.3%-82.0%+118.2%
10-Year ReturnCumulative with dividends-70.9%+85.3%+43.1%-82.0%+465.8%
CAGR (3Y)Annualised 3-year return-19.3%-8.1%-11.8%-43.5%+33.6%
JPM leads this category, winning 6 of 6 comparable metrics.

Risk & Volatility

Evenly matched — TPVG and JPM each lead in 1 of 2 comparable metrics.

TPVG is the less volatile stock with a 0.65 beta — it tends to amplify market swings less than MAIA's 1.84 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. JPM currently trades 95.1% from its 52-week high vs TELO's 40.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricMAIA logoMAIAMAIA Biotechnolog…TPVG logoTPVGTriplePoint Ventu…HRZN logoHRZNHorizon Technolog…TELO logoTELOTelomir Pharmaceu…JPM logoJPMJPMorgan Chase & …
Beta (5Y)Sensitivity to S&P 5001.84x0.65x0.85x1.80x0.94x
52-Week HighHighest price in past year$3.19$7.50$8.46$3.10$337.25
52-Week LowLowest price in past year$0.87$4.48$3.80$1.05$262.71
% of 52W HighCurrent price vs 52-week peak+40.8%+74.3%+51.5%+40.6%+95.1%
RSI (14)Momentum oscillator 0–10047.849.956.948.559.1
Avg Volume (50D)Average daily shares traded771K298K918K144K7.0M
Evenly matched — TPVG and JPM each lead in 1 of 2 comparable metrics.

Analyst Outlook

Evenly matched — HRZN and JPM each lead in 1 of 2 comparable metrics.

Analyst consensus: TPVG as "Hold", HRZN as "Hold", JPM as "Buy". Consensus price targets imply 60.7% upside for TPVG (target: $9) vs -2.5% for HRZN (target: $4). For income investors, HRZN offers the higher dividend yield at 28.76% vs JPM's 1.86%.

MetricMAIA logoMAIAMAIA Biotechnolog…TPVG logoTPVGTriplePoint Ventu…HRZN logoHRZNHorizon Technolog…TELO logoTELOTelomir Pharmaceu…JPM logoJPMJPMorgan Chase & …
Analyst RatingConsensus buy/hold/sellHoldHoldBuy
Price TargetConsensus 12-month target$8.95$4.25$339.75
# AnalystsCovering analysts122261
Dividend YieldAnnual dividend ÷ price+18.4%+28.8%+1.9%
Dividend StreakConsecutive years of raises0115
Dividend / ShareAnnual DPS$1.02$1.25$5.95
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%0.0%0.0%+3.9%
Evenly matched — HRZN and JPM each lead in 1 of 2 comparable metrics.
Key Takeaway

HRZN leads in 1 of 6 categories (Income & Cash Flow). JPM leads in 1 (Total Returns). 4 tied.

Best OverallHorizon Technology Finance … (HRZN)Leads 1 of 6 categories
Loading custom metrics...

MAIA vs TPVG vs HRZN vs TELO vs JPM: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is MAIA or TPVG or HRZN or TELO or JPM a better buy right now?

For growth investors, TriplePoint Venture Growth BDC Corp.

(TPVG) is the stronger pick with 36. 6% revenue growth year-over-year, versus 3. 3% for JPMorgan Chase & Co. (JPM). Horizon Technology Finance Corporation (HRZN) offers the better valuation at 4. 2x trailing P/E (6. 5x forward), making it the more compelling value choice. Analysts rate JPMorgan Chase & Co. (JPM) a "Buy" — based on 61 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — MAIA or TPVG or HRZN or TELO or JPM?

On trailing P/E, Horizon Technology Finance Corporation (HRZN) is the cheapest at 4.

2x versus JPMorgan Chase & Co. at 16. 0x. On forward P/E, TriplePoint Venture Growth BDC Corp. is actually cheaper at 6. 0x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Horizon Technology Finance Corporation wins at 0. 27x versus TriplePoint Venture Growth BDC Corp. 's 5. 88x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

03

Which is the better long-term investment — MAIA or TPVG or HRZN or TELO or JPM?

Over the past 5 years, JPMorgan Chase & Co.

(JPM) delivered a total return of +118. 2%, compared to -82. 0% for Telomir Pharmaceuticals, Inc. Common Stock (TELO). Over 10 years, the gap is even starker: JPM returned +465. 8% versus TELO's -82. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — MAIA or TPVG or HRZN or TELO or JPM?

By beta (market sensitivity over 5 years), TriplePoint Venture Growth BDC Corp.

(TPVG) is the lower-risk stock at 0. 65β versus MAIA Biotechnology, Inc. 's 1. 84β — meaning MAIA is approximately 184% more volatile than TPVG relative to the S&P 500. On balance sheet safety, TriplePoint Venture Growth BDC Corp. (TPVG) carries a lower debt/equity ratio of 133% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

05

Which is growing faster — MAIA or TPVG or HRZN or TELO or JPM?

By revenue growth (latest reported year), TriplePoint Venture Growth BDC Corp.

(TPVG) is pulling ahead at 36. 6% versus 3. 3% for JPMorgan Chase & Co. (JPM). On earnings-per-share growth, the picture is similar: Horizon Technology Finance Corporation grew EPS 756. 3% year-over-year, compared to 1. 5% for JPMorgan Chase & Co.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — MAIA or TPVG or HRZN or TELO or JPM?

TriplePoint Venture Growth BDC Corp.

(TPVG) is the more profitable company, earning 50. 6% net margin versus -6. 6% for Horizon Technology Finance Corporation — meaning it keeps 50. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TPVG leads at 77. 9% versus -4. 0% for HRZN. At the gross margin level — before operating expenses — TPVG leads at 83. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is MAIA or TPVG or HRZN or TELO or JPM more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Horizon Technology Finance Corporation (HRZN) is the more undervalued stock at a PEG of 0. 27x versus TriplePoint Venture Growth BDC Corp. 's 5. 88x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, TriplePoint Venture Growth BDC Corp. (TPVG) trades at 6. 0x forward P/E versus 14. 4x for JPMorgan Chase & Co. — 8. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TPVG: 60. 7% to $8. 95.

08

Which pays a better dividend — MAIA or TPVG or HRZN or TELO or JPM?

In this comparison, HRZN (28.

8% yield), TPVG (18. 4% yield), JPM (1. 9% yield) pay a dividend. MAIA, TELO do not pay a meaningful dividend and should not be held primarily for income.

09

Is MAIA or TPVG or HRZN or TELO or JPM better for a retirement portfolio?

For long-horizon retirement investors, TriplePoint Venture Growth BDC Corp.

(TPVG) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 65), 18. 4% yield). MAIA Biotechnology, Inc. (MAIA) carries a higher beta of 1. 84 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TPVG: +85. 3%, MAIA: -70. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between MAIA and TPVG and HRZN and TELO and JPM?

These companies operate in different sectors (MAIA (Healthcare) and TPVG (Financial Services) and HRZN (Financial Services) and TELO (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: MAIA is a small-cap quality compounder stock; TPVG is a small-cap high-growth stock; HRZN is a small-cap high-growth stock; TELO is a small-cap quality compounder stock; JPM is a large-cap deep-value stock. TPVG, HRZN, JPM pay a dividend while MAIA, TELO do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.